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Cancer development and progression require 
extensive reorganization of extracellular matrix [1, 2]. 
ECM is a complex mixture of structural proteins, 
glycoproteins, and proteoglycans, which provide not 
only essential physical scaffolds to maintain tissues 
structure but also various biochemical signals to 
modulate cellular function. Altering the fine balance of 
ECM signal is sufficient in the long run to induce breast 
cancer development and progression. Although ECM 
has been identified as a determinant factor in the tumor 
microenvironment that controls cancer development and 
progression, but how ECM microenvironmental cues 
integrate at the genome level to promote breast cancer 
progression remains to be determined.
Gene co-expression network analysis is a systems 
biology method using correlation statistics as pairwise 
similarity measurements between gene expression 
profiles to illustrate the strong relationship which 
connects transcripts’ regulatory patterns to the functional 
organization of the cell [3]. Using gene co-expression 
network analysis of more than 700 human breast cancers, 
we have showed that ECM microenvironment is regulated 
at the transcription network level during breast cancer 
development [3]. Importantly, we have identifed Hsp47 
as a hub of the ECM transcription network genes in 
breast cancer tissue [4]. Hsp47 is a protein chaperon 
and facilitates folding and secretion of collagen in the 
endoplasmic reticulum. Hsp47 gene locates at 11q13, a 
region that is often amplified in cancer tissue. Increased 
Hsp47 expression is associated with high cancer stages 
and short recurrent-free survival. We demonstrate that 
Hsp47 promotes tumor growth and invasion by enhancing 
ECM deposition in breast cancer cells [4]. These results 
indicate that Hsp47, possibly through its regulation of 
ECM network, is crucial for cancer progression and may 
represent a potential biomarker and therapeutic target.
Another important finding from the co-expression 
network analysis is the negative association between 
miR-29b/c levels and the ECM network gene expression 
in human breast cancer tissues. MiR-29 has recently 
been identified as a tumor suppressor by altering tumor 
microenvironment [5]. MiR-29 binding sites are enriched 
in the 3′UTR regions of the ECM network genes. 
Moreover, introduction of miR-29 mimics significantly 
reduces the expression of Hsp47 and other ECM network 
genes [4]. These results suggest that miR-29 is a critical 
negative regulator of ECM microenvironment and 
represses ECM protein expression at the transcription 
network level. Given the therapeutic potential of 
microRNA, identifying roles for miR-29 in regulating the 
ECM network may lead to discovery of a novel target for 
the inhibition of ECM-dependent cancer progression.
Stromal cells have been considered major source of 
ECM proteins. However, our and others’ studies demonstrate 
that cancer cells are an active and important component in 
ECM remodeling, and that this process is required for cancer 
progression and metastasis. Cancer cells are an important 
source of ECM in cancer tissue and deposit a significant 
amount collagen, fibronectin, and tenascin-C [6]. However, 
roles of cancer cell–produced ECM in the cancer progression 
have not been appreciated until recently. We show that 
breast cancer cells express multiple ECM transcription 
network genes. Introducing miR-29 or silencing Hsp47 
in breast cancer cells suppresses malignant phenotypes in 
breast cancer cell lines by reducing collagen and fibronectin 
deposition. In addition, silencing Col4A1 or FN1 in breast 
cancer cells represses malignant phenotypes in 3D cultures 
[4]. These results suggest that cancer cell-deposited ECM 
proteins are crucial for cancer progression. Although 
cancer cells and stromal cells in breast cancer tissue both 
generate significant amount of ECM proteins, the roles 
of these proteins in cancer progression may be different. 
It has been shown that LAMA4 produced by cancer cells 
governs primary and metastatic tumor re-initiation [7]. Our 
unpublished data demonstrate cancer cell–produced ECM 
proteins enhance dissemination and survival of tumor cells 
during the early phases of metastasis. These experiments 
provide strong evidence that ECM molecules generated by 
cancer cell promote cancer progression through enhancing 
cell survival and proliferation as essential components of the 
cancer cell niche.
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